NanoSomiX
NanoSomiX is a pioneering company focused on developing non-invasive blood-based testing technologies for neurological disorders using Brain Derived Exosomes (BDE). Their innovative assays aim to improve research and clinical applications by enabling biomarker exploration in neurologic conditions such as Alzheimer’s disease, stroke, traumatic brain injury, and neurodegenerative disorders. With proprietary exosome isolation and analysis technologies covered by multiple patents, NanoSomiX collaborates with academic and industry partners to advance biomarker discovery, diagnosis, and monitoring of brain health through simple blood tests.
Industries
Nr. of Employees
small (1-50)
NanoSomiX
Aliso Viejo, California, United States, North America
Products
Exosome-based blood assay for phosphorylated tau (p-tau)
A blood-based assay that measures p-tau within neuron-derived exosomes as a biomarker associated with Alzheimer’s disease, designed for research and clinical-trial enrichment applications.
Exosome-based blood assay for phosphorylated tau (p-tau)
A blood-based assay that measures p-tau within neuron-derived exosomes as a biomarker associated with Alzheimer’s disease, designed for research and clinical-trial enrichment applications.
Services
Contract research and biomarker assay development
Collaborative and fee-for-service research to confirm detection of brain-derived exosome biomarkers, design study protocols, develop assays, and test clinical or preclinical samples for academic and industry partners.
CLIA laboratory testing for exosome-based blood assays
Laboratory testing services performed in a CLIA-regulated laboratory for blood-based exosome assays, with the ability to transition validated markers to Laboratory Developed Tests.
Contract research and biomarker assay development
Collaborative and fee-for-service research to confirm detection of brain-derived exosome biomarkers, design study protocols, develop assays, and test clinical or preclinical samples for academic and industry partners.
CLIA laboratory testing for exosome-based blood assays
Laboratory testing services performed in a CLIA-regulated laboratory for blood-based exosome assays, with the ability to transition validated markers to Laboratory Developed Tests.
Expertise Areas
- Exosome isolation and characterization
- Blood-based neurological biomarker assay development
- Biomarker discovery and validation for neurologic disorders
- Clinical sample testing and LDT development (CLIA)
Key Technologies
- Immunoaffinity capture of extracellular vesicles
- Two-antibody sandwich immunoassays for vesicle quantification
- ELISA-based protein detection from vesicle preparations
- Surface vs cargo (core) exosome protein analysis